Author: Ken Dropiewski

Bayer (BAY) Release: In Canadian-Led Phase III Clinical Study, Xarelto® When Combined With ASA Significantly Lowered The Combined Risk Of Stroke, Cardiovascular Death, And Heart Attack In Patients With Chronic Coronary Or Peripheral Artery Disease By 24%

  Bleeding rates were low, and while major bleeding was increased, notably, there was no significant increase in intracranial or fatal bleeding1. This combination regimen demonstrated a substantial improvement in net clinical benefit of 20%1. Data from Canadian-led COMPASS study, revealed at ESC Congress 2017, included 27,395 patients globally and […]

Androgen Deprivation Therapy Associated with Higher Risk of Heart Failure in Men with Early-Stage Prostate Cancer

PASADENA, Calif., Aug. 24, 2017 /PRNewswire/ — Men with localized prostate cancer who received androgen deprivation therapy, a hormone treatment, were at significantly higher risk of heart failure than men who did not receive this therapy, according to a Kaiser Permanente study published today in the British Journal of Cancer. In the past, […]

Penumbra, Inc. Announces Participation at Upcoming Investor Conferences

ALAMEDA, Calif., Aug. 24, 2017 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following upcoming investor conferences: Event:         Wells Fargo 2017 Healthcare Conference Location:    Boston, MA at the Westin Boston Waterfront Date:           Thursday, September 7, 2017 Time:          1:40pm ET / 10:40am PT Event:         Morgan […]

Medtronic Receives CE Mark for Attain Stability(TM) Quad MRI SureScan(TM) Active-Fixation Heart Lead

DUBLIN – August 21, 2017 – Medtronic plc (NYSE: MDT) announced it has received CE (Conformité Européene) Mark for the Attain Stability(TM) Quad MRI SureScan(TM) left heart lead. Paired with Medtronic quadripolar cardiac resynchronization therapy-defibrillators (CRT-D) and -pacemakers (CRT-P), the Attain Stability Quad lead features novel, active-fixation technology that is designed […]

Implanted Cardiac Device: Newest Ransomware Target

by Ken Dropiewski, Prime-Core Executive Search (ken@prime-core.com) It has the makings of a plot for a blockbuster movie: a high ranking government official or world leader assassinated by a nefarious hacker who remotely accesses an implanted cardiac device. Plot lines and prominent world leaders notwithstanding, cyber-security risks for implantable cardiac […]

Malin Announces U.S. FDA Approval for New Hourglass™ Peripheral Embolisation Plug

DUBLIN–(BUSINESS WIRE)–Malin Corporation plc. (ISE:MLC, “Malin”), an Irish based and globally operating life sciences company, today announced that its EMBA device, known as the Hourglass™ Peripheral Embolisation Plug, was granted U.S. FDA 510(k) clearance to commence marketing in the US. The Hourglass™ peripheral embolisation plug represents a breakthrough in peripheral […]

Getinge Announces Full U.S. Availability Of Pulsar-18 Self-Expanding Stent From BIOTRONIK For Patients With Peripheral Artery Disease

WAYNE, N.J., Aug. 22, 2017 /PRNewswire/ — Getinge, a leading global provider of innovative medical technology, today announces the full U.S. market release of the Pulsar®-18 stent from BIOTRONIK. Pulsar-18 is the only available self-expanding stent for blocked superficial femoral arteries with a 4-French (4F) delivery system. Getinge currently distributes BIOTRONIK’s portfolio of […]

InspireMD Shares CGuard EPS Video Testimonials From European Key Opinion Leaders

TEL AVIV, ISRAEL–(Marketwired – August 22, 2017) – InspireMD, Inc. (NYSE American: NSPR) (NYSE MKT: NSPR) (NYSE American: NSPR.WS) (NYSE MKT: NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has posted video testimonials about its CGuard™ Embolic Prevention System from […]

InspireMD Announces Notification Of NYSE AMERICAN Listing Deficiency And Expectation To Regain Compliance

TEL AVIV, ISRAEL–(Marketwired – August 22, 2017) – InspireMD, Inc. (NYSE American: NSPR) (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it received a letter from the NYSE American on August 17, 2017 indicating that InspireMD does not […]